Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630697 | 0.90 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL1507267 | 0.85 | NPC1 (0.67) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL25030784 | 0.83 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL1720494 | 0.83 | MAPT (0.72) | KMT2APOLBHTTTDP1ALDH1A1 | |
| SCHEMBL5766528 | 0.82 | NPC1 (0.66) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL14127568 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL15610237 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL5348136 | 0.80 | TPSAB1 (0.70) | SMN1; SMN2NPC1RAB9AGRIN2BKMT2A | |
| SCHEMBL7384158 | 0.80 | KMT2A (0.59) | SMN1; SMN2NPC1RAB9AGRIN2BKMT2A | |
| SCHEMBL14937640 | 0.80 | HPGD (0.52) | SMN1; SMN2NPC1RAB9AGRIN2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | SMN1; SMN2 4057/4885NPC1 3378/4885RAB9A 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.